Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy

Qindeel, Maimoona; Ullah, Muhammad Hameed; Din, Fakhar ud; Ahmed, Naveed; Rehman, Asim Ur

doi:10.1016/j.jconrel.2020.09.016

Cited by 107 publications

(58 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Percutaneous absorption represents an extremely attractive and innovative route of administration. It offers numerous advantages compared with oral and intravenous administration, namely, patient convenience, avoidance of first-pass metabolism and gastrointestinal tract irritants, maintenance of constant target drug concentration, and reductions in the frequency of administration and side effects ( Qindeel et al, 2020b ). However, due to the barrier function of the stratum corneum, penetration of the skin by traditional percutaneous absorption products may be difficult, thereby limiting their clinical use.…”

Section: Strategies For the Manipulation Of Macrophages By Nanomaterialsmentioning

confidence: 99%

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Cai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, progressive, and systemic inflammatory autoimmune disease, characterized by synovial inflammation, synovial lining hyperplasia and inflammatory cell infiltration, autoantibody production, and cartilage/bone destruction. Macrophages are crucial effector cells in the pathological process of RA, which can interact with T, B, and fibroblast-like synovial cells to produce large amounts of cytokines, chemokines, digestive enzymes, prostaglandins, and reactive oxygen species to accelerate bone destruction. Therefore, the use of nanomaterials to target macrophages has far-reaching therapeutic implications for RA. A number of limitations exist in the current clinical therapy for patients with RA, including severe side effects and poor selectivity, as well as the need for frequent administration of therapeutic agents and high doses of medication. These challenges have encouraged the development of targeting drug delivery systems and their application in the treatment of RA. Recently, obvious therapeutic effects on RA were observed following the use of various types of nanomaterials to manipulate macrophages through intravenous injection (active or passive targeting), oral administration, percutaneous absorption, intraperitoneal injection, and intra-articular injection, which offers several advantages, such as high-precision targeting of the macrophages and synovial tissue of the joint. In this review, the mechanisms involved in the manipulation of macrophages by nanomaterials are analyzed, and the prospect of clinical application is also discussed. The objective of this article was to provide a reference for the ongoing research concerning the treatment of RA based on the targeting of macrophages.

show abstract

Section: Strategies For the Manipulation Of Macrophages By Nanomaterialsmentioning

confidence: 99%

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Cai

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…[1,2] The treatment of RA has made important advancements over the past two decades. [3] Biological disease-modifying anti-rheumatic drugs (bDMARDs) provide clinically important improvement in many patients usually failing to respond to symptomatic control with non-steroidal anti-inflammatory drugs or traditional disease-modifying anti-rheumatic drugs. [4,5] Biological agents can reduce inflammation by targeting specific immune pathways, such as tumor necrosis factor-a and interleukin-6 (IL-6), to achieve a better control of symptom and structural damage.…”

Section: Introductionmentioning

confidence: 99%

Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials

Wang

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Concerns exist regarding the potential development of tuberculosis in patients with rheumatoid arthritis (RA) treated with biological and targeted drugs. We assessed systematically whether biological therapy increased the risk of tuberculosis in patients with RA by meta-analysis of randomized controlled trials (RCTs).Methods:A systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and China Biology Medicine disc for RCTs evaluating biological therapy in patients with RA from inception through August 2021. Traditional meta-analysis and network meta-analysis were performed to compare the risk of tuberculosis for each biologics class in patients with RA. Peto odds ratio (Peto OR) and its 95% confidence interval (CI) were calculated as the primary effect measure.Results:In total, 39 studies with 20,354 patients were included in this meta-analysis, and 82 patients developed tuberculosis. The risk of tuberculosis was increased in patients treated with biologics compared with non-biologics (Peto OR: 3.86, 95% CI: 2.36–6.32, P < 0.001). Also, tumor necrosis factor-α (TNF-α) inhibitors had a higher probability of developing tuberculosis than placebo (Peto OR: 3.98, 95% CI: 2.30–6.88, P < 0.001). However, network meta-analysis demonstrated that there was no significant difference in the risk of tuberculosis for each biologics class in patients with RA. Noticeably, tuberculosis was significantly more common in patients treated with a high dose compared with patients receiving a low dose of tofacitinib (Peto OR: 7.39, 95% CI: 2.00–27.31, P = 0.003).Conclusion:This meta-analysis demonstrates the evidence of an elevated risk of tuberculosis in patients with RA treated with TNF-α inhibitors, and a dose-dependent elevated risk of tuberculosis in patients treated with tofacitinib.

show abstract

“…In order to give full play to the advantages of transdermal drug delivery system (TDDS), continuous research is needed, to explore a variety of strategies to promote skin permeability. TDDS are being developed and studied in the treatment of obesity, Parkinsonism, diabetes, smoking cessation, analgesia, Alzheimer’s disease, hypertension, arthritis, osteoporosis, migraine, schizophrenia, and so on [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]. It is an excellent treatment especially for chronic diseases such as obesity that require long-term family treatment.…”

Section: Introductionmentioning

confidence: 99%

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment

Fang

2021

IJMS

View full text Add to dashboard Cite

Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment, but has yet to fully achieve its potential in the treatment of obesity. Obesity has reached epidemic proportions globally and posed a significant threat to human health. Various approaches, including oral and injection administration have widely been used in clinical setting for obesity treatment. However, these traditional options remain ineffective and inconvenient, and carry risks of adverse effects. Therefore, alternative and advanced drug delivery strategies with higher efficacy and less toxicity such as TDD are urgently required for obesity treatment. This review summarizes current TDD technology, and the main anti-obesity drug delivery system. This review also provides insights into various anti-obesity drugs under study with a focus on the recent developments of TDD system for enhanced anti-obesity drug delivery. Although most of presented studies stay in animal stage, the application of TDD in anti-obesity drugs would have a significant impact on bringing safe and effective therapies to obese patients in the future.

show abstract

Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy

Cited by 107 publications

References 92 publications

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment

Contact Info

Product

Resources

About